Jazz Pharmaceuticals Inc. (Nasdaq: JAZZ) will present data from a Phase III clinical trial of its fibromyalgia treatment sodium oxybate. The stock price rocketed $2.85 to $3.87.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.